Bone resorption in chronic otitis media: The role of the osteoclast

ORL

Volumn 64, Issue 2, 2002, Pages 95-107

  Jung, Jae Y ^a   Chole, Richard A ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Campus Box 8115 ^*  (United States)

Author keywords

Bone resorption; Cholesteatoma; Interleukin; Nitric oxide; Osteoclast; Osteopetrosis; Otitis media, chronic; RANKL

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEMBRANE PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROTEIN RANK; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; CELL ASSAY; CHOLESTEATOMA; CHRONIC OTITIS MEDIA; CYTOLOGY; GENE MUTATION; GENETIC ANALYSIS; ONCOGENE C FOS; OSTEOCLAST; OSTEOLYSIS; PATHOLOGY; POLARIZATION; PRIORITY JOURNAL;

ANIMALS; BONE RESORPTION; CHOLESTEATOMA, MIDDLE EAR; CHRONIC DISEASE; CYTOKINES; DISEASE MODELS, ANIMAL; EAR OSSICLES; GENE EXPRESSION; MICE; MICE, KNOCKOUT; NITRIC OXIDE SYNTHASE; OSTEOCLASTS; OTITIS MEDIA; PHENOTYPE;

EID: 0036109032     PISSN: 03011569     EISSN: None     Source Type: Journal    
DOI: 10.1159/000057787     Document Type: Article

References (137)

1. Tumor necrosis factor-alpha mediates orthopedic implant osteolysis
2. The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis
3. General and oral aspects of osteoporosis: A review
4. Rheumatoid arthritis
5. Pressure-induced bone resorption in the middle ear
6. Localization of cytokines in cholesteatoma tissue
7. Pathology of otitis media
8. Keratin particle-induced osteolysis: A mouse model of inflammatory bone remodeling related to cholesteatoma
9. Knowledge about cholesteatoma, from the first description to the modern histopathology
10. Pathogenesis of bone erosions in rheumatoid arthritis
11. Osteoclast activation in inflammatory periodontal diseases
12. Clinical, pathological and immunological aspects of periodontal disease
13. Biologic basis for interleukin-1 in disease
14. Human recombinant interleukin-1 receptor antagonist blocks bone resorption induced by interleukin-1 beta but not interleukin-1 alpha
15. Interleukin 1 (IL-1) and IL-1 receptor antagonist (IL-1-RA) in middle ear cholesteatoma: An analysis of protein production and biological activity
16. In vivo inhibition of localized bone resorption by human recombinant interleukin-1 receptor antagonist
17. Acquired and congenital cholesteatoma: Determination of tumor necrosis factor-alpha, intercellular adhesion molecule-1, interleukin-1-alpha and lymphocyte functional antigen-1 in the inflammatory process
18. Interleukin-1 of cholesteatomatous keratinocytes
19. Interleukin-1 alpha, interleukin-1 beta and interleukin-8 gene expression in human aural cholesteatomas
20. Bone destruction mechanisms in chronic otitis media with cholesteatoma: Specific production by cholesteatoma tissue in culture of bone-resorbing activity attributable to interleukin-1 alpha
21. Role of interleukin 6 in epithelial hyperproliferation and bone resorption in middle ear cholesteatomas
22. Interleukin-6 and tumour necrosis factor alpha synthesized by cholesteatoma cells affect mucociliary function in the eustachian tube
23. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo
24. Endogenous production of tumor necrosis factor by primary cultures of murine calvarial cells: Influence on IL-6 production and osteoclast development
25. Sequential expression of phenotype markers for osteoclasts during differentiation of precursors for multinucleated cells formed in long-term human marrow cultures
26. Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: A possible role of interleukin-6 in osteoclastogenesis
27. The modulation of the expression of IL-6 and its receptor in human osteoblasts in vitro
28. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumor necrosis factors
29. Cholesteatoma debris as an activator of human monocytes. Potentiation of the production of tumor necrosis factor
30. The role of tumor necrosis factor-alpha in bone resorption of cholesteatoma
31. Infusions of recombinant human interleukins 1 alpha and 1 beta cause hypercalcemia in normal mice
32. Activation of osteoclasts by interleukin-1: Divergent responsiveness in osteoclasts formed in vivo and in vitro
33. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand
34. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction
35. Biological activities of prostaglandin analogues and metabolites on bone in organ culture
36. Prostaglandin E2 induces expression of receptor activator of nuclear factor-kappa B ligand/osteoprotegrin ligand on pre-B cells: Implications for accelerated osteoclastogenesis in estrogen deficiency
37. Prostaglandin E2 cooperates with TRANCE in osteoclast induction from hemopoietic precursors: Synergistic activation of differentiation, cell spreading, and fusion
38. Pressures exerted by experimental cholesteatomas
39. Indomethacin inhibition of middle ear bone resorption
40. Ibuprofen inhibits localized bone resorption in the middle ear
41. Fluid shear stress stimulates prostaglandin and nitric oxide release in bone marrow-derived preosteoclast-like cells
42. Cytokine-induced prostaglandin E2 synthesis and cyclooxygenase-2 activity are regulated both by a nitric oxide-dependent and -independent mechanism in rat osteoblasts in vitro
43. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor
44. Nitric oxide in the central nervous system
45. Nitric oxide as modulator of neuronal function
46. Physiology of nitric oxide in skeletal muscle
47. Inhibition of human platelet aggregation by S-nitrosothiols. Heme-dependent activation of soluble guanylate cyclase and stimulation of cyclic GMP accumulation
48. The 1996 Albert Lasker Medical Research Awards. Signal transduction using nitric oxide and cyclic guanosine monophosphate
49. The Michael Mason Prize Essay 1997. Nitric oxide and bone: What a gas!
50. Nitric oxide: A cytokine-induced regulator of bone resorption
51. Nitric oxide: Biphasic dose responses
52. Inhibition of nitric oxide synthase blocks osteoclastic bone resorption in adaptive bone modeling
53. Altered immune responses in mice lacking inducible nitric oxide synthase
54. Nitric oxide synthase expression in bone cells
55. Proinflammatory agents, IL-8 and IL-10, upregulate inducible nitric oxide synthase expression and nitric oxide production in avian osteoclast-like cells
56. Estrogen upregulates endothelial constitutive nitric oxide synthase expression in human osteoblast-like cells
57. Neuropeptides and the puzzle of bone remodeling. Stage of the art
58. Adaptive bone modeling in the middle ear is substance-P dependent
59. In vivo effects of surgical sympathectomy on intramembranous bone resorption
60. Vasoactive intestinal peptide stimulates bone resorption via a cyclic adenosine 3),5)-monophosphate-dependent mechanism
61. C-type natriuretic peptide increases bone resorption in 1.25-dihydroxyvitamin D3-stimulated mouse bone marrow cultures
62. Platelet-derived growth factor in middle ear cholesteatoma
63. Expression of transforming growth factor-alpha (TGF-alpha) in cholesteatoma
64. External and middle ear pathology in TGF-alpha-deficient animals
65. Expression of transforming growth factor-alpha and epidermal growth factor receptor in middle ear cholesteatoma
66. Epidermal growth factor receptor (EGF-R) in human middle ear cholesteatoma: An analysis of protein production and gene expression
67. Angiogenesis and angiogenic growth factors in middle ear cholesteatoma
68. The role of middle ear effusions and epidermal growth factor in cholesteatoma formation in the gerbilline temporal bone
69. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density
70. Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells
71. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis
72. Biochemical characterization of human osteoclast integrins. Osteoclasts express alpha v beta 3, alpha 2 beta 1, and alpha v beta 1 integrins
73. Beta 1 integrins and osteoclast function: Involvement in collagen recognition and bone resorption
74. Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts
75. Microelectrode studies on the acid microenvironment beneath adherent macrophages and osteoclasts
76. The osteoclast clear zone is a specialized cell-extracellular matrix adhesion structure
77. Gelsolin deficiency blocks podosome assembly and produces increased bone mass and strength
78. A new specialized cell-matrix interaction in actively resorbing osteoclasts
79. Endocytic pathway from the basal plasma membrane to the ruffled border membrane in bone-resorbing osteoclasts
80. Osteoclastic acid transport: Mechanism and implications for physiological and pharmacological regulation
81. Carbonic anhydrase and osteoclasts: Localization by labeled inhibitor autoradiography
82. Optimal bone resorption by isolated rat osteoclasts requires chloride/bicarbonate exchange
83. But not cathepsins B, L, or S, is abundantly expressed in human osteoclasts
84. Identification of matrix metalloproteinase 9 in rabbit osteoclasts
85. Bone-resorbing osteoclasts reveal a dynamic division of basal plasma membrane into two different domains
86. Trafficking of matrix collagens through bone-resorbing osteoclasts
87. Two-site immunoassays for osteoclastic tartrate-resistant acid phosphatase based on characterization of six monoclonal antibodies
88. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta
89. Estrogen's bone-protective effects may involve differential IL-1 receptor regulation in human osteoclast-like cells
90. Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase
91. Osteopetrosis in mice lacking haematopoietic transcription factor PU.1
92. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene
93. High extracellular calcium concentrations directly stimulate osteoclast apoptosis
94. Bone and haematopoietic defects in mice lacking c-fos
95. c-fos expression induces bone tumors in transgenic mice
96. A novel target cell for c-fos-induced oncogenesis: Development of chondrogenic tumours in embryonic stem cell chimeras
97. c-Fos: A key regulator of osteoclast-macrophage lineage determination and bone remodeling
98. Pleiotropic effects of a null mutation in the c-fos proto-oncogene
99. Mice deficient in nuclear factor (NF)-kappa B/p52 present with defects in humoral responses, germinal center reactions, and splenic microarchitecture
100. Targeted disruption of the p50 subunit of NF-kappa B leads to multifocal defects in immune responses
101. Requirement for NF-kappaB in osteoclast and B-cell development
102. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines
103. Osteoprotegerin mRNA is increased by interleukin-1 alpha in the human osteosarcoma cell line MG-63 and in human osteoblast-like cells
104. Regulation of osteoprotegerin mRNA levels by prostaglandin E2 in human bone marrow stroma cells
105. Tumor necrosis factor-alpha and -beta upregulate the levels of osteoprotegerin mRNA in human osteosarcoma MG-63 cells
106. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells
107. Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: Down-regulation by glucocorticoids
108. Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells
109. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: Correlation with osteoclast-like cell formation
110. Transforming growth factor-beta1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells
111. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification
112. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function
113. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
114. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells
115. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
116. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: Potential paracrine mechanisms of glucocorticoid-induced osteoporosis
117. Regulation of osteoclast activity
118. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells
119. Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 al-pha,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone
120. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymphnode organogenesis
121. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprote-erin ligand
122. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis
123. RANK is essential for osteoclast and lymph node development
124. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism
125. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling
126. Targeted disruption of the c-src protooncogene leads to osteopetrosis in mice
127. Integrins and signaling in osteoclast function
128. The alpha v beta 3 integrin 'vitronectin receptor'
129. Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice
130. Substrate recognition by osteoclast precursors induces C-src/microtubule association
131. TRAF6 is a signal transducer for interleukin-1
132. Atp6i-deficient mice exhibit severe osteopetrosis due to loss of osteoclast-mediated extracellular acidification
133. Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification
134. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization
135. Mice lacking tartrate-resistant acid phosphatase (Acp 5) have disrupted endochondral ossification and mild osteopetrosis
136. Bone resorption by osteoclasts
137. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families